Trial · NCT03606824
Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
NCT03606824, Not applicable, Unknown, Shaochun.Li
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study). Trials, record NCT03606824. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03606824
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
- NCT number
- NCT03606824
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 248 participants, estimated
- Lead sponsor
- Shaochun.Li
- Conditions
- Dyslipidemia, Subclinical hypothyroïdism, Statin, ASCVD
- Interventions
- Pitavastatin and placebo, Pitavastatin and levothyroxine
- First posted
- 2018-07-31
- Last updated
- 2019-03-20
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of LDL-C levels | Baseline and 6-month. | Absolute change value of serum LDL-C levels between the baseline and 6-month assessment. |
| Secondary | Changes of non-LDL lipid levels (TC, TG, HDL-C, non-HDL-C) | Baseline and 6-month | Absolute change value of serum non-LDL lipid levels (including TC, TG, HDL-C, non-HDL-C) between the baseline and 6-month assessment. |
| Secondary | LDL-C control rate | Baseline and 1-, 2-, 3- and 6-month assessment. | Percentages of patients who had LDL-C values below the treatment goal (LDL-C\<1.8mmol/L) at 1-, 2-, 3- and 6-month assessment. |
| Secondary | Dosage of treatment drugs (pitavastatin and levothyroxine) | At 6-month assessment. | The dosage of pitavastatin and levothyroxine in combination group at 6-month assessment; The dosage of pitavastatin in control group at 6-month assessment |
| Secondary | Levels of thyroid hormones at 6-month assessment | At 6-month assessment. | Levels of thyroid hormones (thyroid-stimulating hormone, free triiodothyronine, free thyroxine, total triiodothyronine, and total thyroxine) at 6-month assessment |
| Secondary | Rates of major adverse cardiac and cerebrovascular events at 6-month assessment | During 6-month follow-up. | Rates of major adverse cardiac and cerebrovascular events (MACCE, including cardiac death, myocardial infarction, target vessel revascularization and cerebrovascular events) during 6 months follow-up. |
| Secondary | Levels of glutamic-pyruvic transaminase (ALT) at 1-, 2-, 3- and 6-month assessment | Baseline and 1-, 2-, 3- and 6-month assessment. | Safety endpoint: live injury parameters, including levels of glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST). |
| Secondary | Levels of glutamic-oxaloacetic transaminase (AST) at 1-, 2-, 3- and 6-month assessment | Baseline and 1-, 2-, 3- and 6-month assessment. | Safety endpoint: live injury parameters, including levels of glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST). |
| Secondary | Levels of serum creatine kinase (CK) at 1-, 2-, 3- and 6-month assessment | Baseline and 1-, 2-, 3- and 6-month assessment. | Safety endpoint: muscle injury parameter--serum creatine kinase (CK) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03606824
GET https://conductscience.org/api/trials/v1/NCT03606824/registered